Skip to main content

Human CD25/IL-2R alpha Biotinylated Antibody

R&D Systems, part of Bio-Techne | Catalog # BAF223

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
BAF223

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

ELISA Detection (Matched Antibody Pair), Western Blot

Cited:

Antibody Array Development

Label

Biotin

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

recombinant human CD25/IL-2 R alpha extracellular domain

Specificity

Detects human CD25/IL-2 R alpha in ELISAs and Western blots. In sandwich immunoassays, less than 0.1% cross-reactivity with recombinant human (rh) IL‑2, rmIL‑2, rpIL‑2, rrIL‑2, rhIL‑2 R beta, and rhIL‑2 R gamma is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Applications for Human CD25/IL-2R alpha Biotinylated Antibody

Application
Recommended Usage

Western Blot

0.1 µg/mL
Sample: Recombinant Human CD25/IL-2 R alpha (Catalog # 223-2A)

Human CD25/IL-2 R alpha Sandwich Immunoassay

ELISA Detection (Matched Antibody Pair)
Recommended Concentration: 0.1-0.4 µg/mL
Use in combination with these reagents:
  • Detection Reagent: Human CD25/IL-2R alpha Antibody (Catalog # MAB623)
  • Standard: Recombinant Human CD25/IL-2R alpha Protein (Catalog # 223-2A)
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CD25/IL-2R alpha

Human IL-2 receptor alpha (IL-2 R alpha), also known as Tac antigen and as CD25, was initially identified as a 55 kDa membrane glycoprotein that is capable of binding IL-2. The IL-2 R alpha cDNA encodes a 272 amino acid residue precursor Type I membrane protein with a 21 residue signal peptide, a 219 residue extracellular region, a 19 residue transmembrane region and a 13 residue cytoplasmic domain. IL-2 R alpha lacks structural features characteristic of members of the cytokine receptor superfamily. By itself, IL-2 R alpha binds IL-2 with low affinity. However, when IL-2 R alpha is associated with the IL-2 receptor beta and gamma chains, a high affinity heterotrimeric receptor complex that transduces IL-2 signals is formed.

Soluble forms of many cytokine receptors have been reported, and a soluble form of IL-2 R alpha (IL-2 sR alpha) appears in serum, concomitant with its increased expression on cells. The function of the soluble IL-2 R alpha is unclear. Increased levels of IL-2 sR alpha in biological fluids reportedly correlate with increased T and B cell activation and immune system activation. Increased serum concentration of IL-2 sR alpha has been observed in patients with a variety of inflammatory conditions and in the course of some leukemias and lymphomas.

Long Name

Interleukin 2 Receptor alpha

Alternate Names

CD25, IL-2 R alpha, IL-2Ra, IL2R alpha, IL2RA

Entrez Gene IDs

3559 (Human); 16184 (Mouse); 25704 (Rat); 403870 (Canine); 102123605 (Cynomolgus Monkey)

Gene Symbol

IL2RA

Additional CD25/IL-2R alpha Products

Product Documents for Human CD25/IL-2R alpha Biotinylated Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human CD25/IL-2R alpha Biotinylated Antibody

For research use only

Loading...
Loading...
Loading...
Loading...